Lv7
5000 积分 2022-08-11 加入
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
18天前
已完结
LBA14 First-in-human phase I study of GTA182, a novel MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted advanced non-small cell lung cancer
1个月前
已关闭
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies
2个月前
已完结
OA08.01 BMS-986504 in Patients With Homozygous MTAP-Deletion (Del): Clinical Results in Patients With NSCLC Enrolled in CA240-0007
2个月前
已关闭
P3.18.71 CA240-0007: BMS-986504 With Anti-PD-1 or Chemotherapy as Treatment for Advanced Solid Tumors With Homozygous MTAP Deletion
2个月前
已完结
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies
2个月前
已完结
How AI agents will change research: a scientist’s guide
2个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
2个月前
已完结
EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates anti-tumor activity in metastatic castration-resistant prostate cancer
2个月前
已完结
[Research Advance on the Role of Spleen Tyrosine Kinase Inhibitors in Hematologic Malignancies]
2个月前
已完结
皖公网安备34019202002308
